FDA approval expands ADC market in first-line TNBC

The FDA expanded Gilead’s Trodelvy label for first-line triple-negative breast cancer, allowing use regardless of PD-L1 status and creating a new competitive front in the TROP2 ADC market. The update enables Trodelvy as monotherapy for patients ineligible for PD-1/L1 inhibitors and in combination with Keytruda for PD-L1-positive tumors with a CPS of at least 10.